Targeting a specialized group of histones is safe and opens new therapeutic opportunities for treating blood cancers. This is the main finding of the latest research by Dr. Marcus Buschbeck and Dr.

It often starts with something as ordinary as tiredness. A lingering fever. Bruises that weren’t there yesterday, for many, these signs don’t ring alarm bells- until they do. June is observed as AML ...

A cross-continental study suggests that in the treatment of acute myeloid leukemia, age affects survival, independent of genetic-risk groups.

A new study has identified a novel strategy for treating acute myelogenous leukemia (AML), an aggressive blood cancer for which the median survival time following diagnosis remains just 8.5 months. A ...

GPS demonstrated promising efficacy and T-cell immune response in AML patients post-second-line salvage therapy in the REGAL trial. Median survival exceeded 13.5 months, surpassing historical data, ...

Single agent and combination data from Phase 1b AML/MDS trial presented at ASH 2024 showed potential of LYT-200 to serve broad range of patients across various lines of treatment LYT-200 is currently ...